{"title":"Digestive Disease Week 2010. Turning Science into Medicine--part 1.","authors":"Lisa Hodgkinson","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>The Digestive Disease Week 2010 conference, held in New Orleans, included topics covering new therapeutic developments in the field of gastroenterology, hepatology, endoscopy and gastrointestinal surgery. This conference report highlights selected presentations on the novel thiopurine-based immunosuppressive agents B-0N and E-1 (both Giuliani SpA/Friedrich-Alexander-Universitaet Erlangen-Nuernberg); the investigation of ML-3403 (c-a-i-r biosciences GmbH), a p38 MAPK inhibitor for the treatment of chronic inflammatory disease; the development of ALV-003 (Alvine Pharmaceuticals Inc) for the treatment of celiac disease; efficacy studies of AST-120 in patients with irritable bowel syndrome; and a clinical trial evaluating linaclotide (Ironwood Pharmaceuticals Inc/Forest Laboratories Inc/Astellas Pharma Inc/Almirall Prodesfarma SA) withdrawal during chronic constipation therapy.</p>","PeriodicalId":55031,"journal":{"name":"Idrugs","volume":"13 7","pages":"421-3"},"PeriodicalIF":0.0000,"publicationDate":"2010-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Idrugs","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
The Digestive Disease Week 2010 conference, held in New Orleans, included topics covering new therapeutic developments in the field of gastroenterology, hepatology, endoscopy and gastrointestinal surgery. This conference report highlights selected presentations on the novel thiopurine-based immunosuppressive agents B-0N and E-1 (both Giuliani SpA/Friedrich-Alexander-Universitaet Erlangen-Nuernberg); the investigation of ML-3403 (c-a-i-r biosciences GmbH), a p38 MAPK inhibitor for the treatment of chronic inflammatory disease; the development of ALV-003 (Alvine Pharmaceuticals Inc) for the treatment of celiac disease; efficacy studies of AST-120 in patients with irritable bowel syndrome; and a clinical trial evaluating linaclotide (Ironwood Pharmaceuticals Inc/Forest Laboratories Inc/Astellas Pharma Inc/Almirall Prodesfarma SA) withdrawal during chronic constipation therapy.
分享
京公网安备 11010802042870号
京ICP备2023020795号-1
求助内容：
应助结果提醒方式：
扫码关注我们
